论文部分内容阅读
宫颈癌的发病率位居我国女性生殖道恶性肿瘤第一位,且近年来发病率有年轻化趋势。目前宫颈癌的治疗以手术及放疗为主,虽然手术技巧和放疗技术已有长足进步,但5年生存率仍然无法让人满意。很多学者致力于研究宫颈癌新的治疗方法,继抗肿瘤血管生成相关研究后抗肿瘤微淋巴管生成成为新的热点,这期间对淋巴管内皮细胞的标记物起了不可忽视的作用。本文概述宫颈癌发病及临床治疗等方面的现状,并总结肿瘤相关、尤其宫颈癌相关微淋巴管研究进展,希望给宫颈癌的生物治疗提供新的思路。
The incidence of cervical cancer in China ranks first in female genital tract cancer, and the incidence of younger trend in recent years. At present, the treatment of cervical cancer is mainly based on surgery and radiotherapy. Although the technique of surgery and radiotherapy have made great progress, the 5-year survival rate is still unsatisfactory. Many scholars devoted themselves to studying the new treatment of cervical cancer. After antitumor angiogenesis-related research, anti-tumor lymphangiogenesis became a new hot spot, which played an important role in the labeling of lymphatic endothelial cells during this period. This article summarizes the current situation of cervical cancer incidence and clinical treatment, and summarizes the progress of tumor-related, especially cervical lymphatic micro-vascular research, hoping to provide new ideas for the biological treatment of cervical cancer.